Spikevax Market Report 2026

Spikevax Market Overview

• The Spikevax market growth in the historic period has been driven by rapid global vaccine deployment during pandemic, large-scale government immunization programs • Market expansion is supported by increasing focus on next-generation mrna vaccines, rising demand for variant-adapted immunizations • Growth Driver: Rising COVID-19 Cases Drive Growth In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Spikevax Market?

Spikevax is a vaccine designed to prevent coronavirus disease 2019 (COVID-19) in individuals aged 6 months and older. It was originally developed with an active ingredient called elasomeran, a messenger RNA (mRNA) molecule that carries genetic instructions for cells to produce a spike protein from the original SARS-CoV-2 strain, helping the immune system recognize and combat the virus. The main clinical indication for spikevax is COVID-19. COVID-19 is a viral respiratory disease caused by SARS-CoV-2, resulting in symptoms such as fever, cough, and breathing issues. Spikevax is an mRNA-based vaccine, which works by instructing cells in the body to produce a protein similar to the spike protein found on the surface of the virus. This helps the immune system recognize and combat the covid virus if it enters the body. Various formulations are available for the spikevax such as spikevax original, spikevax bivalent (original or omicron), and spikevax XBB.1.5. It is distributed through various channels such as government channels, hospitals, and clinics and used by various age groups such as adults, adolescents, and children.

What Is The Spikevax Market Growth Forecast?

The growth in the forecast period can be attributed to increasing focus on next-generation mrna vaccines, rising demand for variant-adapted immunizations, expansion of adult and pediatric vaccination coverage, growing investment in pandemic preparedness, continued innovation in vaccine delivery technologies. Major trends in the forecast period include increasing adoption of mrna vaccine platforms, expansion of variant-specific vaccine formulations, growing focus on booster immunization strategies, enhanced cold-chain optimization for vaccines, rising integration of digital immunization tracking.

Global Spikevax Market Segmentation

1) By Clinical Indication: COVID-19 Primary Prevention, Prevention of Symptomatic COVID-19 Infection, Prevention of COVID-19–Related Mortality, Booster Immunization for COVID-19, Omicron-Lineage COVID-19 Protection 2) By Formulation: Spikevax Original, Spikevax Bivalent (Original Or Omicron), Spikevax XBB.1.5 3) By Age Group: Adults, Adolescents, Children 4) By Distribution Channel: Government Channels, Hospitals, Clinics

What Are The Drivers Of The Spikevax Market?

The rise in the prevalence of COVID cases is expected to propel the growth of the spikevax market going forward. COVID-19 is a disease caused by the SARS-CoV-2 virus, spreading through respiratory droplets and causing symptoms from mild fever to severe respiratory issues. Vaccines and hygiene practices help prevent its spread. COVID-19 cases are increasing due to factors such as new variants, reduced immunity, eased restrictions, seasonal indoor gatherings, and uneven vaccine coverage. Spikevax treat COVID-19 by teaching the immune system to recognize and combat the virus through an mRNA-induced spike protein, offering strong protection against severe disease and variants. For instance, in March 2023, according to a report published by the Office for National Statistics, a UK-based government department for official statistics, as of March 2023, an estimated 1.9 million people in the UK (2.9% of the population) reported long COVID. Most (92%) had COVID-19 over 12 weeks earlier, with 69% experiencing symptoms for over a year and 41% for over two years. Therefore, the rise in the prevalence of COVID cases will drive the growth of the spikevax industry forward. The rise in healthcare investments is expected to drive the growth of the spikevax market going forward. Healthcare investments refer to the total amount spent on healthcare services, including medical treatments, medications, and hospital care, within a specific period. Healthcare investments are rising due to factors such as an aging population, increasing healthcare needs, advancements in medical technology, and rising prices for services and medications. Healthcare investments drive Spikevax adoption by funding vaccine procurement, enhancing infrastructure, and improving delivery systems, thereby ensuring wider accessibility and supporting public health efforts. For instance, In May 2024, according to a report published by the Office for National Statistics, a UK-based government department for official statistics, total healthcare expenditure saw a 5.6% increase in nominal terms from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth observed in 2022. Therefore, the rise in healthcare investments is going to drive the growth of the spikevax industry forward.

Key Players In The Global Spikevax Market

Major companies operating in the spikevax market are Moderna Inc.

What Are Latest Mergers And Acquisitions In The Spikevax Market?

In September 2024, Moderna, Inc., a U.S.-based biotechnology company, entered into a joint commercialization agreement with Cenra Healthcare, for Moderna’s mRNA respiratory vaccine portfolio, including Spikevax (mRNA-1273). With this agreement, Moderna will lead manufacturing, distribution, and supply, while Cenra Healthcare will take responsibility for local medical education, promotion, and market access in Taiwan. Cenra Healthcare Inc the Taiwan-based partner, specializes in healthcare services, government contracting, and biologics commercialization.

Regional Insights

North America was the largest region in the spikevax market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Spikevax Market?

The spikevax market consists of sales of COVID-19 vaccines, bivalent booster vaccines, syringes, and needles. Values in this market are ‘factory gate’ values, representing the value of vaccines sold directly by manufacturers, either to governments, healthcare organizations, or distribution networks. This includes revenues from related services but excludes resales further along the supply chain or integration into other healthcare products.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Spikevax Market Report 2026?

The spikevax market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the spikevax industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.